Clinical trials: Multiple Myleoma, open to volunteers
Hypogammaglobulinemia, Bacterial Infections
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period will reduce the rate of major bacterial infections per participant per year in…
- Conditions
- Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma
- Trial name
- EXCELL (NCT05645107)
- Testing
- Xembify
- Where
- 62 sites in United States, Bosnia and Herzegovina and 6 more
- Volunteers
- 386 people
- Sponsor
- Grifols Therapeutics LLC
Multiple Myleoma, Multiple Myeloma in Relapse
Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma
The goal of this clinical trial is to evaluate the efficacy of Teclistamab (Te) and autologous lymphocyte infusions (ALI) in relapse refractory multiple myeloma.
- Conditions
- Multiple Myleoma, Multiple Myeloma in Relapse, Multiple Myeloma Refractory
- Trial name
- TALIM (NCT06880601)
- Testing
- Teclistamab
- Volunteers
- 52 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Multiple Myleoma
GR1803 Injection in Patients With RRMM
All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event)…
- Trial name
- NCT06952075
- Testing
- GR1803
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.